-
SCIENCE: Fecal microbiota transplantation may help eliminate resistance to immunotherapy in patients with melanoma
Time of Update: 2021-06-16
This study proves that it is possible to reprogram the tumor microenvironment to manipulate the microbiome to enhance and improve the immunotherapy effect of advanced melanoma and overcome anti- PD-1 resistance .
-
ASCO2021: Atezolizumab + Bevacizumab combination therapy is beneficial for unresectable liver cancer
Time of Update: 2021-06-16
Finn , MD, University of California, Los Angeles, presented the updated IMbrave150 results, stating that “ atezolizumab + bevacizumab has the longest overall survival in the first-line phase III study of advanced liver cancer , confirming that This combination serves as the standard treatment for previously untreated, unresectable liver cancer, "Richard S.
-
During ASCO 2021, Ma Jun's team has another major research on nasopharyngeal cancer
Time of Update: 2021-06-16
1016/ S0140-6736(21)01123-5On June 8, during the 2021 American Society of Clinical Oncology (ASCO) annual meeting, "The Lancet" published online a phase 3 randomized controlled clinical trial led by the team of Professor Ma Jun from the Cancer Center Affiliated to Sun Yat-sen University and participating in 14 hospitals in China Result .
-
ASCO2021: Patritumab Deruxtecan produces durable response in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer patients
Time of Update: 2021-06-16
The results of a phase I dose escalation and dose expansion study (U31402-A-U102,) showed that Patritumab deruxtecan has a long-lasting effect in patients with non-small cell lung cancer , regardless of the EGFR tyrosine kinase inhibitor resistance mechanism .
-
A major breakthrough!
Time of Update: 2021-06-16
It is worth noting that at the just-concluded American Society of Clinical Oncology ( ASCO ) annual meeting , the KEYNOTE-177 study announced the final analysis results, the results showed that for MSI-H/dMMR metastatic or unresectable colorectal cancer patients In other words, the immunotherapeutic drug pembrolizumab as a first-line treatment is far superior to traditional chemotherapy regimens in efficacy and safety, and at the same time satisfies the goals of long-term, precise and safe effects .
-
JNCI: The best endocrine choice after adjuvant chemotherapy for perimenopausal breast cancer patients
Time of Update: 2021-06-16
The study showed that for patients with ER+ breast cancer aged 45-50 years, the best endocrine therapy after adjuvant chemotherapy after surgery is treatment containing aromatase inhibitors (AI) .
-
up to date!
Time of Update: 2021-06-16
Human Reproduction is a peer-reviewed scientific journal covering all aspects of human reproduction, including reproductive physiology and pathology, endocrinology, andrology, gonadal function, gametogenesis, fertilization, embryonic development, implantation, pregnancy, genetics, Preimplantation genetic diagnosis , oncology, infectious diseases .
-
up to date!
Time of Update: 2021-06-16
Impact factor (abbreviated IF) refers to a certain journal The frequency of cited articles in a particular year or period is an important indicator of the influence of academic journalsEugene Garfield (1925–2017) Eugene Garfield was one of the most influential figures in library and information science in the second half of the 20th century .
-
JCO: Efficacy and safety of Atezolizumab + bevacizumab + chemotherapy in the initial diagnosis of stage III or IV ovarian cancer: a placebo-controlled randomized phase III study (IMagyn050/GOG 3015/ENGOT- OV39)
Time of Update: 2021-06-16
research summary research summaryIn an intent-to-population (ITT) analysis, the median PFS of the atilizumab group and the placebo group were 19.
In an intent-to-population (ITT) analysis, the median PFS of the atilizumab group and the placebo group were 19.
-
Hepatology: Adjuvant radiotherapy can effectively consolidate the curative effect of narrow margin hepatectomy for liver cancer
Time of Update: 2021-06-16
In summary, adjuvant radiotherapy is an effective, well-tolerated and promising adjuvant treatment plan, suitable for HCC patients undergoing narrow margin hepatectomy .
Phase II study of adjuvant radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma .
-
Eur J Cancer: The actual clinical efficacy of olaparib monotherapy in the treatment of gBRCAm-HER2-negative metastatic breast cancer
Time of Update: 2021-06-16
In the Phase III OlympiAD trial, olaparib significantly prolonged the progression-free progression of human epidermal growth factor 2 (HER2) negative metastatic breast cancer (mBC) patients with BRCA germline mutation (gBRCAm) compared with the chemotherapy determined by the doctor Lifetime (PFS) .
-
Clin Cancer Res: Efficacy of Pyrotinib in the treatment of HER2+ breast cancer patients with brain metastases: a real-world multicenter study
Time of Update: 2021-06-16
This study is a real-world study evaluating the OS, PFS, tumor mutation burden (TMB), clinical benefit rate (CBR) and objective response of Pyrotinib in the treatment of HER2+ breast cancer patients with brain metastases (BM) Rate (ORR) .
-
Lancet: Nivolumab + chemotherapy is significantly better than chemotherapy alone for advanced gastroesophageal adenocarcinoma
Time of Update: 2021-06-16
This article reports the preliminary results of nivolumab combined with chemotherapy compared to chemotherapy alone for such patientsThe CheckMate 649 study is a multi-center, randomized, open-label Phase 3 clinical trial that recruited untreated, unresectable, non-HER2-positive, non-HER2 positive patients who were over 18 years old from 175 hospitals and cancer centers in 29 countries Patients with gastric, gastroesophageal junction or esophageal adenocarcinoma, regardless of the expression of PD-1/L1 .
-
Metz Tumor Progress Express (Issue 008)
Time of Update: 2021-06-16
Studies believe that Sotorasib has shown good therapeutic effects and good safety in KRASp. G12C mutant non-small cell lung cancer patients who have previously received platinum chemotherapy or immunotherapy .
-
Lancet's subsidiary RET inhibitor--Pralsetinib in the treatment of thyroid cancer, achieves a breakthrough in survival!
Time of Update: 2021-06-16
The overall response rate of patients with RET-mutant medullary thyroid cancer who did not respond to treatment was 15/21 (71%) (95% CI 48-89), and patients who had previously received cabozantinib and/or vandetanib It was 33/55 (60%) (95% CI 46-73) and 8/9 (89%) (95% CI 52-100) in patients with RET fusion-positive thyroid cancer .
-
JAMA Oncol: Efficacy and safety of Pembrolizumab combined with concurrent chemoradiotherapy (cCRT) in the treatment of unresectable stage III NSCLC: KEYNOTE-799.
Time of Update: 2021-06-16
In summary, Pembrolizumab combined with concurrent chemotherapy and radiotherapy (cCRT) is a feasible strategy for the treatment of unresectable stage III NSCLC with controllable toxicity .
-
Lancet oncol: Unknown factors significantly affect the risk of colorectal cancer in patients with Lynch syndrome
Time of Update: 2021-06-16
To estimate the difference in colorectal cancer penetrance between carriers of pathogenic variants of the same geneThis is a retrospective cohort study that obtained data from the International Mismatch Repair Consortium, which is composed of 273 members from 122 research centers or clinics in 32 countries on six continents and is dedicated to the study of Lynch syndrome .
-
Blood: Elderly patients with multiple myeloma can be maintained with low-dose lenalidomide after Rd induction chemotherapy
Time of Update: 2021-06-16
Lenalidomide-dexamethasone (Rd) is the standard treatment for elderly patients with multiple myeloma (MM)This is a randomized Phase 3 study, which aims to evaluate the efficacy of dose/plan-adjusted Rd following maintenance of Nalidomide 10 mg/day (Rd-R) versus Rd-continuous treatment for newly diagnosed elderly patients with MM who are moderately healthy And feasibility .
-
Blood: Targeting PRMT1-mediated FLT3 methylation can enhance the clearance of MLL rearranged ALL cells
Time of Update: 2021-06-16
Compared with treatment with FLT3 tyrosine kinase inhibitor PKC412 alone, PKC412 combined with MS023 treatment can enhance the clearance of MLL-r ALL cellsSummary diagramSummary diagramIn summary, the results of this study indicate that the elimination of FLT3 arginine methylation by inhibiting PRMT1 represents a promising therapeutic strategy targeting MLL-r ALL cells .
-
Agendia presents data from the innovative FLEX study at ASCO 2021, demonstrating the utility of MammaPrint and BluePrint to a broad category of patient groups
Time of Update: 2021-06-16
ER-basal cell-like tumors BluePrint genome expression profile is very different Close, provide clinical actionable information to guide neoadjuvant treatment decisions • FLEX real-world filing database will recruit 10,000 breast cancer patients by the end of 2021, and the ultimate goal is to recruit a total of 30,000 casesBreast cancerAgendia, Inc.
